Abstract
Various vaccine platforms were developed and deployed against the COVID-19 disease. The Fc-mediated functions of IgG antibodies are essential in the adaptive immune response elicited by vaccines. However, the long-term changes of protein subunit vaccines and their combinations with mRNA vaccines are unknown. A total of 272 serum and plasma samples were collected from individuals who received first to third doses of the protein subunit Medigen, the mRNA (BNT), or the adenovector AstraZeneca vaccines. The IgG subclass level was measured using enzyme-linked immunosorbent assay, and Fc-N glycosylation was measured using LC-MS/MS. Antibody-dependent phagocytosis (ADCP) and complement deposition (ADCD) of anti-spike (S) IgG antibodies were measured. IgG1 and 3 reached the highest anti-S IgG subclass level. IgG1, 2, and 4 subclass levels significantly increased in mRNA- and Medigen-vaccinated individuals. Fc-glycosylation was stable, except in female BNT vaccinees, who showed increased bisection and decreased galactosylation. Female BNT vaccinees had a higher anti-S IgG titer than that of males. ADCP declined in all groups. ADCD increased in Medigen-vaccinated individuals after the third dose. Each vaccine produced specific long-term changes in Fc structure and function. This finding is critical when selecting a vaccine platform or combination to achieve the desired immune response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (grant number: EMRPD1N0071) and "National Institutes of Health, USA (grant number: U01 AI151698) for the United World Antiviral Research Network (UWARN)."
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Diagnostics Investigational Review Board of Cummaquid, MA, USA gave ethical approval of the sample collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data availability statement
Funding statement The authors have declared no competing interest.
Conflict of interest disclosure This project was funded by the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (grant number: EMRPD1N0071)
Ethics approval statement Patient serum and plasma samples were collected as per protocol SDP-003, Human Biological Specimens Collection, dated September 22, 2017, and the qualifications of the principal investigator (Robert Pyrtle, M.D.) were reviewed and approved by the Diagnostics Investigational Review Board (Cummaquid, MA, USA, IRB No.: 202001041A3C).
Patient consent statement
Abstract was updated and funding source was added.
Data Availability
The samples were collected as per protocol SDP-003, Human Biological Specimens Collection, data September 22, 2017 and qualifications of the principal investigator (Robert Pyrtle, M.D.) were reviewed and approved by the Di- agnostics Investigational Review Board (Cummaquid, MA, USA).
